1Czuczman M S, Dodge R K, Stewart C C, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group BStudy 8364. Blood, 1999, 93:3931-3939.
2Hoelzer D, Arnold R, Freund M, et al. Characteristics, outcome and risk factors in adult T-lineage acute lymphoblastic leukemia(ALL). Blood, 1999, 94:2926a-2926a.
3Miwa H, Kita K, Mishii K, et al. Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood, 1993, 82:3445-3445.
4Faded S, Kantarjian H M, Talpaz M, et al. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood, 1998, 91: 3995 - 4019.
5Thomas D A, Cortes J, O'Brien S, et al. Hyper-CVADprogram in Burkit's-type adult acute lymphoblastic leukemia. J Clin Oncol, 1999, 17:2461-2470.
6Ludwig W D, Rieder H, Bartram C R, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult Pro-B acute lymphoblastic leukemia: results of the german multicenter trials GMALL 03/87 and 04/89. Blood, 1998, 92:1898-1909.
7Schoch C, Rieder H, Freund M, et al. Twenty-three cases of acute lymphoblastic leukemia with translocation t (4 ; 11 ) (q21 ; q23): the implication of additional chromosomal aberrations. Ann Hematol, 1995, 70:195 -201.
9Crist W M, Carroll A J, Shuster J J, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t ( 1; 19) (q23; p1 3 ): a Pediatric Oncology Group study. Blood, 1990, 76:117-122.
10Kantarjian H M, OBrien S, Smith T L, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol, 2000, 18:547-547.
